DO ART NCD Analysis

20 April, 2022

# Tables 1-3: Descriptive statistics

* Table 1: Descriptive statistics of cardiovascular risk in the DO ART study, by trial arm and gender
* Table 2 (Appendix): Change in cardiovascular risk from baseline to endline, by trial arm and gender
* Table 3 (Appendix): Descriptive statistics of cardiovascular risk in the DO ART study, by site [SUGGEST CUTTING]

### Page Break

## Table 1: Descriptive statistics of cardiovascular risk in the DO ART study, by trial arm and gender (N = 1315)

|  | **Category** | **Clinic Arm   N (%)** | **Community Arm   N (%)** | **Hybrid Arm   N (%)** | **Women   N (%)** | **Men   N (%)** | **Total   N (%)** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Age | 18-39 | 320 (72%) | 314 (74%) | 322 (73%) | 485 (75%) | 471 (71%) | 956 (73%) |
| 40-59 | 117 (26%) | 106 (25%) | 115 (26%) | 154 (24%) | 184 (28%) | 338 (26%) |
| 60+ | 9 (2%) | 7 (2%) | 5 (1%) | 10 (2%) | 11 (2%) | 21 (2%) |
| Gender | Women | 216 (48%) | 208 (49%) | 225 (51%) | -- | -- | 649 (49%) |
| Men | 230 (52%) | 219 (51%) | 217 (49%) | -- | -- | 666 (51%) |

| **ii) Lifestyle and other risk** | **Category** | **Clinic Arm   N (%)** | **Community Arm   N (%)** | **Hybrid Arm   N (%)** | **Women   N (%)** | **Men   N (%)** | **Total   N (%)** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Smoking Status   [Baseline] | Not at all | 342 (77%) | 319 (75%) | 350 (79%) | 615 (95%) | 396 (59%) | 1011 (77%) |
| Former | 6 (1%) | 3 (1%) | 3 (1%) | 3 (0%) | 9 (1%) | 12 (1%) |
| Current - occasional | 20 (4%) | 30 (7%) | 22 (5%) | 15 (2%) | 57 (9%) | 72 (5%) |
| Current - frequent | 78 (17%) | 75 (18%) | 67 (15%) | 16 (2%) | 204 (31%) | 220 (17%) |
| Days of exercise (per week)   [Endline] | 5-7 | 65 (15%) | 76 (18%) | 73 (17%) | 83 (13%) | 131 (20%) | 214 (16%) |
| 3-4 | 154 (35%) | 143 (33%) | 159 (36%) | 211 (33%) | 245 (37%) | 456 (35%) |
| 1-2 | 123 (28%) | 97 (23%) | 102 (23%) | 173 (27%) | 149 (22%) | 322 (24%) |
| 0 | 56 (13%) | 68 (16%) | 49 (11%) | 106 (16%) | 67 (10%) | 173 (13%) |
| Unknown | 48 (11%) | 43 (10%) | 59 (13%) | 76 (12%) | 74 (11%) | 150 (11%) |
| Vegetable intake   [Endline] | Always or usually | 75 (17%) | 104 (24%) | 75 (17%) | 136 (21%) | 118 (18%) | 254 (19%) |
| Sometimes | 198 (44%) | 195 (46%) | 192 (43%) | 310 (48%) | 275 (41%) | 585 (44%) |
| Never or rarely | 142 (32%) | 94 (22%) | 120 (27%) | 141 (22%) | 215 (32%) | 356 (27%) |
| Unknown | 31 (7%) | 34 (8%) | 55 (12%) | 62 (10%) | 58 (9%) | 120 (9%) |
| Prior stroke or heart attack   [Endline] | No | 410 (92%) | 385 (90%) | 387 (88%) | 580 (89%) | 602 (90%) | 1182 (90%) |
| Yes | 5 (1%) | 8 (2%) | 1 (0%) | 8 (1%) | 6 (1%) | 14 (1%) |
| Unknown | 31 (7%) | 34 (8%) | 54 (12%) | 61 (9%) | 58 (9%) | 119 (9%) |

| **iii) Cardiovascular Risk** | **Category** | **Clinic Arm   N (%)** | **Community Arm   N (%)** | **Hybrid Arm   N (%)** | **Women   N (%)** | **Men   N (%)** | **Total   N (%)** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Blood pressure   [Endline] | Normal | 212 (48%) | 219 (51%) | 217 (49%) | 336 (52%) | 312 (47%) | 648 (49%) |
| Elevated | 95 (21%) | 64 (15%) | 76 (17%) | 104 (16%) | 131 (20%) | 235 (18%) |
| Hypertension Stage 1 | 93 (21%) | 101 (24%) | 95 (21%) | 141 (22%) | 148 (22%) | 289 (22%) |
| Hypertension Stage 2 | 15 (3%) | 21 (5%) | 10 (2%) | 19 (3%) | 27 (4%) | 46 (3%) |
| Missing | 31 (7%) | 22 (5%) | 44 (10%) | 49 (8%) | 48 (7%) | 97 (7%) |
| BMI (kg/m^2)   [Endline] | <18.5 | 14 (3%) | 17 (4%) | 13 (3%) | 10 (2%) | 34 (5%) | 44 (3%) |
| 18.5-24.9 | 212 (48%) | 188 (44%) | 181 (41%) | 225 (35%) | 356 (53%) | 581 (44%) |
| 25-29.9 | 113 (25%) | 127 (30%) | 126 (29%) | 207 (32%) | 159 (24%) | 366 (28%) |
| 30+ | 72 (16%) | 50 (12%) | 69 (16%) | 147 (23%) | 44 (7%) | 191 (15%) |
| Missing | 35 (8%) | 45 (11%) | 53 (12%) | 60 (9%) | 73 (11%) | 133 (10%) |
| Hemoglobin A1C (%)   [Endline] | Normal | 300 (67%) | 254 (59%) | 258 (58%) | 421 (65%) | 391 (59%) | 812 (62%) |
| Prediabetes | 24 (5%) | 18 (4%) | 26 (6%) | 27 (4%) | 41 (6%) | 68 (5%) |
| Diabetes | 3 (1%) | 2 (0%) | 6 (1%) | 4 (1%) | 7 (1%) | 11 (1%) |
| Missing | 119 (27%) | 153 (36%) | 152 (34%) | 197 (30%) | 227 (34%) | 424 (32%) |
| Total cholesterol (mg/dL)   [Endline] | Normal | 393 (88%) | 348 (81%) | 352 (80%) | 534 (82%) | 559 (84%) | 1093 (83%) |
| Borderline High | 4 (1%) | 8 (2%) | 3 (1%) | 9 (1%) | 6 (1%) | 15 (1%) |
| High | 0 (0%) | 1 (0%) | 2 (0%) | 2 (0%) | 1 (0%) | 3 (0%) |
| Missing | 49 (11%) | 70 (16%) | 85 (19%) | 104 (16%) | 100 (15%) | 204 (16%) |
| 10-year CVD risk score   [Endline] | <10% | 264 (59%) | 209 (49%) | 237 (54%) | 445 (69%) | 265 (40%) | 710 (54%) |
| 10% to <20% | 60 (13%) | 62 (15%) | 53 (12%) | 6 (1%) | 169 (25%) | 175 (13%) |
| 20% to <30% | 1 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (0%) | 1 (0%) |
| 30% to <40% | 1 (0%) | 2 (0%) | 0 (0%) | 0 (0%) | 3 (0%) | 3 (0%) |
| Missing | 120 (27%) | 154 (36%) | 152 (34%) | 198 (31%) | 228 (34%) | 426 (32%) |

### Page break

## (Appendix) Table 2: Change in cardiovascular risk from baseline to endline, by trial arm and gender (AHRI site only, N = 350)

| **Change in CVD risk** |  | **Clinic Arm   Mean (SE)** | **Community Arm   Mean (SE)** | **Hybrid Arm   Mean (SE)** | **Women   Mean (SE)** | **Men   Mean (SE)** | **Total   Mean (SE)** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Change in BMI, baseline to endline   [AHRI only] |  | 0.9 (0.3) | 0.9 (0.3) | 0.4 (0.3) | 0.5 (0.2) | 0.9 (0.2) | 0.7 (0.2) |
| Change in Systolic Blood pressure, baseline to endline   [AHRI only] |  | 0.8 (1.4) | 0.5 (1.4) | 3.7 (1.7) | 1.1 (1.3) | 2.1 (1.2) | 1.6 (0.9) |

### Page break

## (Appendix) Table 3: Descriptive statistics of cardiovascular risk in the DO ART study, by site (N = 873)

* *[SUGGEST CUTTING]*
* This table excludes the hybrid arm, for comparability with the later regression analysis

|  | **Category** | **Midlands KZN SA   N (%)** | **Northern KZN SA   N (%)** | **SW Uganda   N (%)** | **Total   N (%)** |
| --- | --- | --- | --- | --- | --- |
| Age | 18-39 | 168 (71%) | 324 (74%) | 142 (72%) | 634 (73%) |
| 40-59 | 63 (27%) | 110 (25%) | 50 (25%) | 223 (26%) |
| 60+ | 6 (3%) | 5 (1%) | 5 (3%) | 16 (2%) |
| Gender | Women | 107 (45%) | 225 (51%) | 92 (47%) | 424 (49%) |
| Men | 130 (55%) | 214 (49%) | 105 (53%) | 449 (51%) |

| **ii) Lifestyle and other risk** | **Category** | **Midlands KZN SA   N (%)** | **Northern KZN SA   N (%)** | **SW Uganda   N (%)** | **Total   N (%)** |
| --- | --- | --- | --- | --- | --- |
| Smoking Status   [Baseline] | Not at all | 181 (76%) | 318 (72%) | 162 (82%) | 661 (76%) |
| Former | 4 (2%) | 2 (0%) | 3 (2%) | 9 (1%) |
| Current - occasional | 9 (4%) | 31 (7%) | 10 (5%) | 50 (6%) |
| Current - frequent | 43 (18%) | 88 (20%) | 22 (11%) | 153 (18%) |
| Days of exercise (per week)   [Endline] | 5-7 | 18 (8%) | 16 (4%) | 107 (54%) | 141 (16%) |
| 3-4 | 52 (22%) | 208 (47%) | 37 (19%) | 297 (34%) |
| 1-2 | 74 (31%) | 132 (30%) | 14 (7%) | 220 (25%) |
| 0 | 53 (22%) | 67 (15%) | 4 (2%) | 124 (14%) |
| Unknown | 40 (17%) | 16 (4%) | 35 (18%) | 91 (10%) |
| Vegetable intake   [Endline] | Always or usually | 16 (7%) | 108 (25%) | 55 (28%) | 179 (21%) |
| Sometimes | 68 (29%) | 265 (60%) | 60 (30%) | 393 (45%) |
| Never or rarely | 138 (58%) | 50 (11%) | 48 (24%) | 236 (27%) |
| Unknown | 15 (6%) | 16 (4%) | 34 (17%) | 65 (7%) |
| Prior stroke or heart attack   [Endline] | No | 218 (92%) | 414 (94%) | 163 (83%) | 795 (91%) |
| Yes | 4 (2%) | 9 (2%) | 0 (0%) | 13 (1%) |
| Unknown | 15 (6%) | 16 (4%) | 34 (17%) | 65 (7%) |

| **iii) Cardiovascular Risk** | **Category** | **Midlands KZN SA   N (%)** | **Northern KZN SA   N (%)** | **SW Uganda   N (%)** | **Total   N (%)** |
| --- | --- | --- | --- | --- | --- |
| Blood pressure   [Endline] | Normal | 117 (49%) | 220 (50%) | 94 (48%) | 431 (49%) |
| Elevated | 44 (19%) | 104 (24%) | 11 (6%) | 159 (18%) |
| Hypertension Stage 1 | 47 (20%) | 89 (20%) | 58 (29%) | 194 (22%) |
| Hypertension Stage 2 | 13 (5%) | 12 (3%) | 11 (6%) | 36 (4%) |
| Missing | 16 (7%) | 14 (3%) | 23 (12%) | 53 (6%) |
| BMI (kg/m^2)   [Endline] | <18.5 | 8 (3%) | 13 (3%) | 10 (5%) | 31 (4%) |
| 18.5-24.9 | 122 (51%) | 169 (38%) | 109 (55%) | 400 (46%) |
| 25-29.9 | 60 (25%) | 153 (35%) | 27 (14%) | 240 (27%) |
| 30+ | 29 (12%) | 90 (21%) | 3 (2%) | 122 (14%) |
| Missing | 18 (8%) | 14 (3%) | 48 (24%) | 80 (9%) |
| Hemoglobin A1C (%)   [Endline] | Normal | 183 (77%) | 255 (58%) | 116 (59%) | 554 (63%) |
| Prediabetes | 25 (11%) | 10 (2%) | 7 (4%) | 42 (5%) |
| Diabetes | 4 (2%) | 0 (0%) | 1 (1%) | 5 (1%) |
| Missing | 25 (11%) | 174 (40%) | 73 (37%) | 272 (31%) |
| Total cholesterol (mg/dL)   [Endline] | Normal | 203 (86%) | 418 (95%) | 120 (61%) | 741 (85%) |
| Borderline High | 5 (2%) | 2 (0%) | 5 (3%) | 12 (1%) |
| High | 1 (0%) | 0 (0%) | 0 (0%) | 1 (0%) |
| Missing | 28 (12%) | 19 (4%) | 72 (37%) | 119 (14%) |
| 10-year CVD risk score   [Endline] | <10% | 157 (66%) | 210 (48%) | 106 (54%) | 473 (54%) |
| 10% to <20% | 51 (22%) | 55 (13%) | 16 (8%) | 122 (14%) |
| 20% to <30% | 1 (0%) | 0 (0%) | 0 (0%) | 1 (0%) |
| 30% to <40% | 2 (1%) | 0 (0%) | 1 (1%) | 3 (0%) |
| Missing | 26 (11%) | 174 (40%) | 74 (38%) | 274 (31%) |

### Page Break

# Regression Analysis

* Table 4: Poisson regressions for community delivery of HIV care compared with clinic-based care
* Table 5: Linear regressions for community delivery of HIV care compared with clinic-based care
* Table 6: Poisson regressions, including VS
* Table 7: Linear regressions, including VS
* Table 8: Poisson regressions with VS as predictor [NON-RANDOMIZED ANALYSIS]
* Table 9: Linear regressions with VS as predictor [NON-RANDOMIZED ANALYSIS]
* Table 10: Poisson regressions, stratified by site *[SUGGEST CUTTING]*
* Table 11: Linear regressions, stratified by site *[SUGGEST CUTTING]*

### Page Break

## Table 4. Relative risk of elevated cardiovascular risk for community delivery of HIV care compared with clinic-based care (N = 873).

* Relative risk is estimated using a quasipoisson model with robust SEs (and log link).
* Baseline model adjusts for site only
* Adjusted models includes site, age, smoking and gender.
* The adjusted model for “Overall CVD risk” includes a 3-way interaction term age, smoking and gender. [only this model includes the interaction term]

|  | **Baseline Analysis** | | | **Adjusted Analysis** | | |
| --- | --- | --- | --- | --- | --- | --- |
| **Variable** | **Relative Risk** | **95% CI** | **p-value** | **Adj. Relative Risk** | **Adj. 95% CI** | **Adj. p-value** |
| Elevated overall 10-year CVD risk | 1.23 | (0.91,1.68) | 0.183 | 1.13 | (1.01,1.25) | 0.027 |
| Elevated BP | 0.91 | (0.77,1.07) | 0.251 | 0.91 | (0.77,1.07) | 0.267 |
| Overweight (BMI >= 25) | 1 | (0.87,1.16) | 0.954 | 1 | (0.87,1.15) | 0.964 |
| Elevated blood sugar (a1c >= 5.7) | 0.94 | (0.54,1.63) | 0.835 | 0.92 | (0.53,1.58) | 0.751 |
| Elevated lipids (total cholesterol >= 200) | 2.89 | (0.92,9.11) | 0.069 | 2.97 | (0.98,8.96) | 0.054 |

### Page Break

## Table 5: Cardiovascular risk difference for community delivery of HIV care compared with clinic care (N = 873).

* Risk difference is estimated using a linear model with robust SEs.
* Baseline model adjusts for site only
* Adjusted models include site, age, smoking and gender (but no interaction terms).

|  | **Baseline Analysis** | | | **Adjusted Analysis** | | |
| --- | --- | --- | --- | --- | --- | --- |
| **Variable** | **Risk Difference** | **95% CI** | **p-value** | **Adj. Risk Difference** | **Adj. 95% CI** | **Adj. p-value** |
| Systolic blood pressure (mmHg) | -1.12 | (-2.66,0.43) | 0.157 | -1.02 | (-2.55,0.51) | 0.191 |
| Diastolic blood pressure (mmHg) | 0 | (-1.25,1.25) | 0.999 | 0.04 | (-1.2,1.28) | 0.952 |
| BMI (kg/m^2) | -0.17 | (-0.83,0.49) | 0.619 | -0.2 | (-0.83,0.44) | 0.541 |
| Hemoglobin A1c (%) | 0.04 | (-0.04,0.12) | 0.374 | 0.04 | (-0.04,0.11) | 0.383 |
| Total cholesterol (mg/dL) | 3.52 | (-0.16,7.19) | 0.061 | 3.7 | (0.06,7.34) | 0.046 |

### Page Break

## Table 6. Relative risk of elevated cardiovascular risk for community delivery of HIV care compared with clinic-based care, *adjusted for endline viral suppression* (N = 873).

* Relative risk is estimated using a quasipoisson model with robust SEs (and log link).
* Baseline model adjusts for site and endline viral suppression [binary]
* Adjusted models include site, age, smoking, gender, and endline viral suppression [binary]
* The adjusted model for “Overall CVD risk” includes a 3-way interaction term age, smoking and gender. [only this model includes the interaction term]

|  | **Baseline Analysis** | | | **Adjusted Analysis** | | |
| --- | --- | --- | --- | --- | --- | --- |
| **Variable** | **Relative Risk** | **95% CI** | **p-value** | **Adj. Relative Risk** | **Adj. 95% CI** | **Adj. p-value** |
| Elevated overall 10-year CVD risk | 1.29 | (0.94,1.76) | 0.11 | 1.15 | (1.03,1.29) | 0.012 |
| Elevated BP | 0.92 | (0.77,1.08) | 0.312 | 0.92 | (0.78,1.08) | 0.316 |
| Overweight (BMI >= 25) | 0.98 | (0.84,1.13) | 0.735 | 0.99 | (0.86,1.14) | 0.853 |
| Elevated blood sugar (a1c >= 5.7) | 1 | (0.57,1.73) | 0.992 | 0.97 | (0.56,1.68) | 0.909 |
| Elevated lipids (total cholesterol >= 200) | 2.71 | (0.87,8.44) | 0.085 | 2.85 | (0.93,8.73) | 0.066 |

### Page Break

## Table 7: Cardiovascular risk difference for community delivery of HIV care compared with clinic care, *adjusted for endline viral suppression status* (N = 873).

* Risk difference is estimated using a linear model with robust SEs.
* Baseline model adjusts for site and endline viral suppression [binary]
* Adjusted models include site, age, smoking, gender, and endline viral suppression [binary] (but no interaction terms)

|  | **Baseline Analysis** | | | **Adjusted Analysis** | | |
| --- | --- | --- | --- | --- | --- | --- |
| **Variable** | **Risk Difference** | **95% CI** | **p-value** | **Adj. Risk Difference** | **Adj. 95% CI** | **Adj. p-value** |
| Systolic blood pressure (mmHg) | -0.94 | (-2.5,0.61) | 0.235 | -0.86 | (-2.41,0.68) | 0.273 |
| Diastolic blood pressure (mmHg) | 0.12 | (-1.13,1.36) | 0.854 | 0.15 | (-1.08,1.38) | 0.813 |
| BMI (kg/m^2) | -0.31 | (-0.97,0.35) | 0.356 | -0.29 | (-0.93,0.34) | 0.36 |
| Hemoglobin A1c (%) | 0.04 | (-0.04,0.12) | 0.314 | 0.04 | (-0.04,0.12) | 0.32 |
| Total cholesterol (mg/dL) | 3.23 | (-0.46,6.92) | 0.086 | 3.42 | (-0.25,7.08) | 0.067 |

### Page Break

## Table 8. Relative risk of elevated cardiovascular risk for people virally suppressed, versus those not virally suppressed at endline (N = 1315). [NON-RANDOMIZED ANALYSIS]

* Relative risk is estimated using a quasipoisson model with robust SEs (and log link).
* This analysis does NOT include trial arm.
* Baseline model adjusts for site only
* Adjusted models include site, age, smoking, and gender
* The adjusted model for “Overall CVD risk” includes a 3-way interaction term age, smoking and gender. [only this model includes the interaction term]

|  | **Baseline Analysis** | | | **Adjusted Analysis** | | |
| --- | --- | --- | --- | --- | --- | --- |
| **Variable** | **Relative Risk** | **95% CI** | **p-value** | **Adj. Relative Risk** | **Adj. 95% CI** | **Adj. p-value** |
| Elevated overall 10-year CVD risk | 0.85 | (0.64,1.11) | 0.237 | 0.96 | (0.88,1.04) | 0.298 |
| Elevated BP | 1 | (0.86,1.16) | 0.959 | 1.02 | (0.88,1.18) | 0.813 |
| Overweight (BMI >= 25) | 1.29 | (1.13,1.48) | 0 | 1.21 | (1.06,1.38) | 0.004 |
| Elevated blood sugar (a1c >= 5.7) | 0.92 | (0.58,1.46) | 0.728 | 0.98 | (0.63,1.54) | 0.945 |
| Elevated lipids (total cholesterol >= 200) | 1.01 | (0.35,2.92) | 0.983 | 1 | (0.35,2.86) | 0.997 |

### Page Break

## Table 9: Cardiovascular risk difference for people virally suppressed, versus those not virally suppressed at endline (N = 1315). [NON-RANDOMIZED ANALYSIS]

* Risk difference is estimated using a linear model with robust SEs. son model with robust SEs (and log link).
* This analysis does NOT include trial arm.
* Baseline model adjusts for site
* Adjusted models include site, age, smoking, and gender (but no interaction terms)

|  | **Baseline Analysis** | | | **Adjusted Analysis** | | |
| --- | --- | --- | --- | --- | --- | --- |
| **Variable** | **Risk Difference** | **95% CI** | **p-value** | **Adj. Risk Difference** | **Adj. 95% CI** | **Adj. p-value** |
| Systolic blood pressure (mmHg) | -0.49 | (-1.84,0.85) | 0.471 | -0.35 | (-1.68,0.98) | 0.608 |
| Diastolic blood pressure (mmHg) | -0.3 | (-1.39,0.78) | 0.582 | -0.26 | (-1.34,0.81) | 0.633 |
| BMI (kg/m^2) | 1.28 | (0.71,1.86) | 0 | 0.95 | (0.39,1.51) | 0.001 |
| Hemoglobin A1c (%) | -0.01 | (-0.08,0.07) | 0.887 | -0.01 | (-0.08,0.07) | 0.85 |
| Total cholesterol (mg/dL) | 4.81 | (1.46,8.17) | 0.005 | 4.65 | (1.31,7.99) | 0.006 |

### Page Break

# Table 10: Relative risk of elevated cardiovascular risk for community delivery of HIV care compared with clinic-based care, stratified by site *[SUGGEST CUTTING]*

* Relative risk is estimated using a quasipoisson model with robust SEs (and log link).
* Adjusted models include age, smoking and gender.
* The adjusted model for “Overall CVD risk” includes a 3-way interaction term age, smoking and gender.
* Viral suppression is NOT included

| **Midlands KZN SA** | **Baseline Analysis** | | | **Adjusted Analysis** | | |
| --- | --- | --- | --- | --- | --- | --- |
| **Variable** | **Relative Risk** | **95% CI** | **p-value** | **Adj. Relative Risk** | **Adj. 95% CI** | **Adj. p-value** |
| Elevated overall 10-year CVD risk | 1.06 | (0.66,1.7) | 0.806 | 1.06 | (0.97,1.16) | 0.217 |
| Elevated BP | 0.94 | (0.75,1.17) | 0.556 | 0.96 | (0.78,1.19) | 0.724 |
| Overweight (BMI >= 25) | 0.96 | (0.81,1.13) | 0.624 | 0.95 | (0.82,1.11) | 0.552 |
| Elevated blood sugar (a1c >= 5.7) | 0.68 | (0.2,2.36) | 0.546 | 0.72 | (0.21,2.46) | 0.601 |
| Elevated lipids (total cholesterol >= 200) | 45131646.08 | (11360483.64,179293905.23) | 0 | 227741300.7 | (67649840.13,766684739.27) | 0 |

| **SW Uganda** | **Baseline Analysis** | | | **Adjusted Analysis** | | |
| --- | --- | --- | --- | --- | --- | --- |
| **Variable** | **Relative Risk** | **95% CI** | **p-value** | **Adj. Relative Risk** | **Adj. 95% CI** | **Adj. p-value** |
| Elevated overall 10-year CVD risk | 1.54 | (0.64,3.71) | 0.341 | 1.32 | (NaN,NaN) | NaN |
| Elevated BP | 0.83 | (0.55,1.24) | 0.357 | 0.79 | (0.53,1.18) | 0.249 |
| Overweight (BMI >= 25) | 1.13 | (0.6,2.14) | 0.711 | 1.11 | (0.59,2.1) | 0.737 |
| Elevated blood sugar (a1c >= 5.7) | 0.45 | (0.09,2.13) | 0.311 | 0.45 | (0.1,2.06) | 0.306 |
| Elevated lipids (total cholesterol >= 200) | 0.91 | (0.16,5.23) | 0.912 | 0.88 | (0.14,5.37) | 0.887 |

| **Northern KZN SA** | **Baseline Analysis** | | | **Adjusted Analysis** | | |
| --- | --- | --- | --- | --- | --- | --- |
| **Variable** | **Relative Risk** | **95% CI** | **p-value** | **Adj. Relative Risk** | **Adj. 95% CI** | **Adj. p-value** |
| Elevated overall 10-year CVD risk | 1.34 | (0.85,2.13) | 0.206 | 1.05 | (0.88,1.25) | 0.58 |
| Elevated BP | 0.9 | (0.65,1.26) | 0.555 | 0.9 | (0.65,1.25) | 0.539 |
| Overweight (BMI >= 25) | 1.09 | (0.79,1.51) | 0.581 | 1.05 | (0.77,1.42) | 0.768 |
| Elevated blood sugar (a1c >= 5.7) | 1.27 | (0.64,2.49) | 0.495 | 1.22 | (0.62,2.39) | 0.56 |
| Elevated lipids (total cholesterol >= 200) | 6.74 | (0.8,56.7) | 0.079 | 5.92 | (0.88,39.84) | 0.068 |

### Page Break

# Table 11: Cardiovascular risk difference for community delivery of HIV care compared with clinic care, stratified by site *[SUGGEST CUTTING]*

* Risk difference is estimated using a linear model with robust SEs.
* Adjusted models include age, smoking and gender (but no interaction terms).
* Viral suppression is NOT included

| **Midlands KZN SA** | **Baseline Analysis** | | | **Adjusted Analysis** | | |
| --- | --- | --- | --- | --- | --- | --- |
| **Variable** | **Risk Difference** | **95% CI** | **p-value** | **Adj. Risk Difference** | **Adj. 95% CI** | **Adj. p-value** |
| Systolic blood pressure (mmHg) | -0.69 | (-2.39,1.01) | 0.428 | -0.54 | (-2.22,1.14) | 0.528 |
| Diastolic blood pressure (mmHg) | 0.08 | (-1.4,1.57) | 0.912 | 0.2 | (-1.26,1.65) | 0.792 |
| BMI (kg/m^2) | -0.35 | (-1.35,0.65) | 0.494 | -0.39 | (-1.34,0.55) | 0.414 |
| Hemoglobin A1c (%) | 0.02 | (-0.1,0.14) | 0.726 | 0.03 | (-0.09,0.15) | 0.643 |
| Total cholesterol (mg/dL) | 3.65 | (-0.94,8.25) | 0.119 | 3.97 | (-0.62,8.56) | 0.09 |

| **SW Uganda** | **Baseline Analysis** | | | **Adjusted Analysis** | | |
| --- | --- | --- | --- | --- | --- | --- |
| **Variable** | **Risk Difference** | **95% CI** | **p-value** | **Adj. Risk Difference** | **Adj. 95% CI** | **Adj. p-value** |
| Systolic blood pressure (mmHg) | -3.44 | (-7.59,0.71) | 0.104 | -3.63 | (-7.74,0.47) | 0.083 |
| Diastolic blood pressure (mmHg) | -1.22 | (-4.53,2.09) | 0.469 | -1.28 | (-4.55,1.99) | 0.442 |
| BMI (kg/m^2) | 0.2 | (-0.75,1.14) | 0.684 | 0.19 | (-0.76,1.14) | 0.694 |
| Hemoglobin A1c (%) | 0.07 | (-0.1,0.23) | 0.425 | 0.08 | (-0.08,0.23) | 0.34 |
| Total cholesterol (mg/dL) | -0.66 | (-9.99,8.67) | 0.89 | -1.15 | (-10.45,8.16) | 0.809 |

| **Northern KZN SA** | **Baseline Analysis** | | | **Adjusted Analysis** | | |
| --- | --- | --- | --- | --- | --- | --- |
| **Variable** | **Risk Difference** | **95% CI** | **p-value** | **Adj. Risk Difference** | **Adj. 95% CI** | **Adj. p-value** |
| Systolic blood pressure (mmHg) | -0.1 | (-3.49,3.28) | 0.953 | -0.16 | (-3.41,3.09) | 0.921 |
| Diastolic blood pressure (mmHg) | 0.81 | (-1.76,3.39) | 0.537 | 0.55 | (-1.96,3.07) | 0.666 |
| BMI (kg/m^2) | -0.06 | (-1.31,1.19) | 0.921 | -0.24 | (-1.38,0.9) | 0.679 |
| Hemoglobin A1c (%) | 0.04 | (-0.1,0.18) | 0.603 | 0.04 | (-0.1,0.18) | 0.609 |
| Total cholesterol (mg/dL) | 5.73 | (-1.98,13.45) | 0.145 | 5.47 | (-2.12,13.06) | 0.158 |